2020年发表在医学杂志StatPearls上的一项研究显示,每年大约有150万人患心肌炎.

来源: 5181 于 2022-06-07 15:26:15 [档案] [旧帖] [给我悄悄话] 本文已被阅读：次 (6868 bytes)

回答: Here is the report from 澳洲统计：由 va168 于 2022-06-07 15:04:26

https://www.chinanews.com.cn/gj/2021/05-24/9484166.shtml

2020年发表在医学杂志StatPearls上的一项研究显示，每年大约有150万人患心肌炎，相当于每10万人中有10至20例.

mrna疫苗引起的心肌炎更多.

Myocarditis and pericarditis with mRNA vaccines

Myocarditis (inflammation of the heart) and pericarditis (inflammation of the membrane around the heart) are rare effects on the heart that may occur after vaccination with the mRNA vaccines Comirnaty (Pfizer) and Spikevax (Moderna). Cases typically occur within 10 days, and usually resolve after a few days following treatment and rest. In Australia, myocarditis is reported in 1–2 out of every 100,000 people after receiving the Comirnaty (Pfizer) vaccine. While it is more commonly reported in young men and teenage boys after the second dose (6–11 cases in 100,000 people), it remains rare.

The number of reports of myocarditis is increasing each week, which is expected as the number of vaccine doses given also increases each week. We are closely monitoring the rates of myocarditis for all age groups and sex.

While there are some fluctuations from week to week, especially in subgroups with small numbers of reports, rates of reporting of myocarditis in Australia are consistent with rates reported internationally.

Myocarditis is seen much more commonly in people who become infected with COVID-19 than in people who are vaccinated. A preliminary study from the United States(link is external) found the rate of myocarditis in young men after COVID-19 is approximately 45 cases per 100,000 infections. It is important to note that this study has not yet been peer-reviewed. These findings are consistent with other information published by the Centers for Disease Control and Prevention in the US on myocarditis as a complication of COVID-19 infection(link is external). The Australian Technical Advisory Group on Immunisation (ATAGI) continues to emphasise that the protective benefits of the mRNA vaccines far outweigh the rare risk of these side effects in all eligible age groups(link is external).

We encourage people to seek medical attention if they experience symptoms that could suggest myocarditis or pericarditis. This includes chest pain, palpitations (irregular heartbeat), fainting or shortness of breath, particularly if they occur within 1–5 days of vaccination.

Initial tests for those presenting with symptoms include ECG, troponin levels and chest X-ray. Brief guidance on the initial assessment of children and adolescents with symptoms has been published by the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network(link is external).

ATAGI advises that people who develop myocarditis attributed to their first vaccine dose should defer further doses of an mRNA COVID-19 vaccine and discuss this with their treating doctor.